Supervisors info:
Αθανάσιος Χαντζάρας, Δόκτωρ Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών (ΕΚΠΑ), μέλος της επιστημονικής Επιτροπής Αξιολόγησης και Αποζημίωσης Φαρμάκων του Υπουργείου Υγείας.
Original Title:
Η βραχυπρόθεσμη σχέση κόστους - αποτελεσματικότητας της από του στόματος χορηγούμενης Σεμαγλουτίδης έναντι Εμπαγλιφλοζίνης, Σιταγλιπτίνης και Λιραγλουτίδης για τη θεραπεία του Σακχαρώδους Διαβήτη τύπου 2 στην Ελλάδα
Translated title:
Short-term cost-effectiveness of oral semaglutide versus empagliflozin, sitagliptin, and liraglutide in type 2 diabetes treatment in Greece
Summary:
Background
Oral semaglutide represents the first GLP-1 receptor agonist that is orally administered and
has demonstrated its efficacy in treating type 2 diabetes throughout the PIONEER clinical trial programme. This study evaluates the cost per patient, achieving treatment targets with oral semaglutide versus empagliflozin, sitagliptin, and liraglutide in diabetes patients in Greece.
Methods
Seven endpoints were examined: 1) HbA1c ≤6,5%, 2) HbA1c < 7%, 3) ≥1%-point HbA1c
reduction, 4) HbA1c <7% without hypoglycemia, 5) weight loss ≥5%, 6) weight loss ≥10%,
7) ≥1%-point HbA1c reduction and weight loss ≥3%. The proportion of patients achieving
these endpoints was sourced from the PIONEER 2,3, and 4 trials, and treatment costs were calculated over an annual time horizon in 2024 EUR, based on retail prices and excluding the co-payment of patients. The cost of control was calculated by dividing the annual treatment cost by the percentage of patients achieving each treatment target.
Results
The annual treatment costs were EUR 1.210,04 for oral semaglutide, EUR 528,04 for
empagliflozin, EUR 260,51 for sitagliptin, and EUR 1.542,87 for liraglutide. Although a
higher proportion of patients achieved treatment goals with oral semaglutide, it presented a higher cost of control across most endpoints compared to empagliflozin (mean PSA difference: EUR 839,45) and sitagliptin (mean PSA difference: EUR 1.041,50). In contrast, oral semaglutide had a consistently lower cost of control compared to liraglutide across all treatment targets (mean PSA difference: EUR -3.779,23).
Conclusion
The analysis confirms that oral semaglutide's cost of control varies significantly based on
the treatment target, suggesting that without changes in its ex-factory price or net price, it
might not be the most cost-effective option compared to empagliflozin and sitagliptin in
Greece.
Keywords:
Cost of control, short-term cost effectiveness, Type 2 diabetes, GLP-1 receptor agonists, Oral semaglutide, Greece
